The Nordic region (Sweden, Denmark, Norway, Finland, Iceland) is highly regarded as one of the most advanced places to develop and access high quality data. These countries boast arguably the world’s most advanced healthcare systems, with strong levels of access to the latest medicines, so they continue to be an attractive place to run clinical trials as well as prospective real world studies. However, because every patient has a unique patient number from birth to death, these countries are unique in terms of tracking patient-level data. The Nordic healthcare systems offer a unique opportunity for life science researchers to access these high-quality, granular-level, validated, external data sources. Retrospective or pragmatic studies in the Nordic region, if performed correctly, are a unique and unequaled opportunity to generate high-quality evidence that can help pharma and medtech companies understand and demonstrate the value of their medicines to physicians, payers and patients in the region and beyond.

5 Reasons to attend -You will learn:

1. Learn how to take advantage of the Nordic region for clinical, real-world and pragmatic studies, especially through accessing unique external data sources.
2. Market Access, HEOR, Reimbursement professionals: Understand reimbursement pathways and the evidence requirements of payers and HTAs.
3. Medical Affairs Professionals: Appreciate how to leverage the power of medical affairs to develop evidence and communicate it’s value to stakeholders.
4. Medical Device industry executives: Obtain the latest information on how to navigate complex reimbursement pathways for advanced devices and diagnostics
5. Network with the regions thought leaders, stakeholders and experts, especially at the exclusive networking dinner. Have your questions answered through interactive panel discussions.

Request agenda here for complete speaker list

PAYERS, HTAS & POLICY MAKERS

Head of Healthcare Development Department
Stockholm County Council, Sweden

Managing Director & CEO
IHE - Swedish Institute for Health Economics, Sweden

Associate Director of Medicines Optimisation, DGS & Swale CCGs
NHS, UK

CEO
Healthcare DENMARK

Associate Professor in Medical Ethics Centre for Research Ethics & Bioethics
Uppsala University, Sweden

Business Development Officer
NIHR Clinical Research Network

Strategic Advisor
Amgros, Denmark

PATIENTS

Founder and CEO, Lupus Friends and Family Foundation
Chairwoman, EUPATI, Denmark

Patient Representative & Inclusion Advocate Chair: Access Matters, Midstream,
Board Member; European Forum for Good Clinical Practice (EFGCP), Healthcare Quality Improvement Partnership (HQIP), International Foundation for Integrated Care (IFIC), UK

PHARMA INDUSTRY

Senior Director, Real World Evidence
Janssen, Sweden

Director, Feasibility Lead
Pfizer, UK

Head of RWE and Epidemiology,
Janssen, Sweden

Nordic Medical Officer
Kyowa Kirin, Finland

Market Access Lead
Bristol-Myers Squibb, Sweden

Value & HTA Lead, Nordics
Bristol-Myers Squibb

Nordic Market Access and Public Affairs Manager
Sandoz, Sweden

Global Patient Outcomes and Real-World Evidence International Scientist, Nordic
Eli Lilly, Sweden

Vice President, Europe Area Medical Director
GSK, UK

Medical Director, Nordic & Benelux,
Otsuka, Sweden

Medical Director Nordic/Baltic,
Kyowa Kirin, Sweden

Nordic Medical Affairs Director,
Janssen, Sweden

Senior Adviser, Manager of Research and Development
The Association for Pharma Industry, Legemiddelindustrien (LMI), Norway

Medical Affairs Manager Lymphoma
Janssen, Sweden

MEDTECH INDUSTRY

Consultant, R&D
BTG International, UK

Global Market Access Manager
EMEA, Abbott, UK

Director,Global Market Access & HEOR EMEA Lead
Abbott, UK

Medical Officer and VP of Clinical Affairs
Össur, Iceland

Product Specialist Surgical
Stryker, Norway

Request agenda here for complete speaker list

Pictures from recent Nordic Leaders Forum. Imagine being there...

In this workshop we will go through the pathways and processes for Medtech in the four Nordic Countries. The DRG system is partially shared across the countries through the Nord-DRG collaboration and Sweden will be used as case-study to explain the dynamics. The workshop will include detailed step-by-step descriptions of how to establish market access. The format will allow for interaction throughout the process to enable discussion about the specific market access questions you have at hand.

  • Nordic overview and comparison of the countries
    • DRG systems
    • HTA processes
  • Swedish DRG system
    • Utility of DRG in funding
    • Analyzing the current DRG payments
    • How to initiate change
  • Swedish HTA framework
    • Regional HTA’s
    • TLV and national assessment of medical devices and medical aids.
  • Norwegian HTA framework
    • Regional
    • National HTA
Workshop Leader

Mattias Kyhlstedt
CEO and founder
Synergus RWE, Sweden

 

SPEAKER LIST - DAY 1

Consultant, R&D
BTG International, UK

Senior Director, Real World Evidence
Janssen, Sweden

Director, Feasibility Lead
Pfizer, UK

Business Development Officer
NIHR Clinical Research Network

Head of RWE and Epidemiology,
Janssen, Sweden

Nordic Medical Officer
Kyowa Kirin, Finland

Global Market Access Manager
EMEA, Abbott, UK

Director,Global Market Access & HEOR EMEA Lead
Abbott, UK

CEO
Healthcare DENMARK

Associate Professor in Medical Ethics Centre for Research Ethics & Bioethics
Uppsala University, Sweden

Founder and CEO, Lupus Friends and Family Foundation
Chairwoman, EUPATI, Denmark

Patient Representative & Inclusion Advocate Chair: Access Matters, Midstream,
Board Member; European Forum for Good Clinical Practice (EFGCP), Healthcare Quality Improvement Partnership (HQIP), International Foundation for Integrated Care (IFIC), UK

 

This stream will discuss the payer and HTA agencies’ challenges in budget management and cost-containment, compared to their enthusiasm to reimburse expensive treatments and diagnostics. Participants will learn how drugs and technologies of high clinical and economic benefit will be assessed by payers, and how they can further develop, measure, demonstrate and deliver this value to health systems.

SPEAKER LIST - DAY 2 - STREAM 1

Head of Healthcare Development Department
Stockholm County Council, Sweden

Market Access Lead
Bristol-Myers Squibb, Sweden

Value & HTA Lead, Nordics
Bristol-Myers Squibb

Managing Director & CEO
IHE - Swedish Institute for Health Economics, Sweden

Nordic Market Access and Public Affairs Manager
Sandoz, Sweden

Global Patient Outcomes and Real-World Evidence International Scientist, Nordic
Eli Lilly, Sweden

Associate Director of Medicines Optimisation, DGS & Swale CCGs
NHS, UK

  1. Understand how medical affairs are at the forefront of new pharmaceutical industry commercial models and what needs to be done to maximise success.

  2. Discover which are the most intelligent ways to map, communicate with and engage with Nordic KOLs and other prescribers, payers, patient groups, pharmacies and tomorrow’s stakeholders.

  3. Measure the performance of your medical affairs and MSL teams and individuals to improve effectiveness.

  4. Benchmark with experts to find out the best practices in late phase research, especially observational studies, patient registries and investigator-initiated studies in the Nordic region.

SPEAKER LIST - DAY 2 - STREAM 2

Vice President, Europe Area Medical Director
GSK, UK

Medical Director, Nordic & Benelux,
Otsuka, Sweden

Medical Director Nordic/Baltic,
Kyowa Kirin, Sweden

Nordic Medical Affairs Director,
Janssen, Sweden

Medical Affairs Manager Lymphoma
Janssen, Sweden

Medical Officer and VP of Clinical Affairs
Össur, Iceland

Product Specialist Surgical
Stryker, Norway

 

Media Partners

This event is accredited for CPD (Continuing Professional Development) status

Share with Colleagues